Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

NCT00469729 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

101

Enrollment

OTHER

Sponsor class

Conditions

Hematologic Malignancies
Acute Myeloid Leukemia
Lymphoid Leukemia
Chronic Myeloid Leukemia
Hodgkin's Disease
Non-Hodgkin's Lymphoma
Myelodysplastic Syndromes

Interventions

DRUG: StemEx®

Sponsor

Gamida Cell -Teva Joint Venture Ltd.